William Blair upgrades Nektar to Outperform following promising long-term data for rezpegaldesleukin in atopic dermatitis treatment with improved safety profile. The results met and in some cases exceeded investor expectations.
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.
Kymera Therapeutics (KYMR) shares surge after Phase 1b trial shows KT-621 oral pill achieves Dupixent-like efficacy in treating moderate to severe eczema with favorable safety profile.
Morgan Stanley upgrades Vertex Pharmaceuticals on promising kidney pipeline progress and downgrades Regeneron due to balanced risk/reward and valuation concerns.
Regeneron's Eylea HD receives FDA approval for treating macular edema from retinal vein occlusion with flexible dosing options, potentially reducing injection frequency.
Regeneron Pharmaceuticals exceeds Q3 2025 expectations with $3.75B revenue, driven by blockbuster eczema drug Dupixent and cancer treatment Libtayo, despite Eylea competition challenges.
